June 13, 2022

SomaLogic inks license deal with OncoHost to develop precision cancer diagnostics

Original source here.

  • SomaLogic (NASDAQ:SLGC) on Monday said it had signed a licensing agreement with Israel-based OncoHost for the development of precision cancer diagnostics.
  • As per the agreement, OncoHost will license SLGC’s SomaScan Platform to develop proteomics tests for its PROphet diagnostic system, which analyzes and monitors biological processes in a patient in response to a given cancer therapy.
  • As part of the deal, OncoHost will establish a lab in North Carolina where it will use the SomaScan Assay kits to run protein measurements on patient samples.